BTK and B-cell chronic lymphocytic leukemia: Agents like the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax are highly effective in CLL and induce deep remissions, also in patients that relapse after chemotherapy [2,3].